-
DEMO: Dose Exploration, Monitoring, and Optimization Using a Biological Mediator for Clinical Outcomes
Authors:
Cheng-Han Yang,
Peter F. Thall,
Ruitao Lin
Abstract:
Phase 1-2 designs provide a methodological advance over phase 1 designs for dose finding by using both clinical response and toxicity. A phase 1-2 trial still may fail to select a truly optimal dose. because early response is not a perfect surrogate for long term therapeutic success. To address this problem, a generalized phase 1-2 design first uses a phase 1-2 design's components to identify a se…
▽ More
Phase 1-2 designs provide a methodological advance over phase 1 designs for dose finding by using both clinical response and toxicity. A phase 1-2 trial still may fail to select a truly optimal dose. because early response is not a perfect surrogate for long term therapeutic success. To address this problem, a generalized phase 1-2 design first uses a phase 1-2 design's components to identify a set of candidate doses, adaptively randomizes patients among the candidates, and after longer follow up selects a dose to maximize long-term success rate. In this paper, we extend this paradigm by proposing a design that exploits an early treatment-related, real-valued biological outcome, such as pharmacodynamic activity or an immunological effect, that may act as a mediator between dose and clinical outcomes, including tumor response, toxicity, and survival time. We assume multivariate dose-outcome models that include effects appearing in causal pathways from dose to the clinical outcomes. Bayesian model selection is used to identify and eliminate biologically inactive doses. At the end of the trial, a therapeutically optimal dose is chosen from the set of doses that are acceptably safe, clinically effective, and biologically active to maximize restricted mean survival time. Results of a simulation study show that the proposed design may provide substantial improvements over designs that ignore the biological variable.
△ Less
Submitted 2 April, 2024;
originally announced April 2024.
-
A Bayesian Feature Allocation Model for Identification of Cell Subpopulations Using Cytometry Data
Authors:
Arthur Lui,
Juhee Lee,
Peter F. Thall,
May Daher,
Katy Rezvani,
Rafet Barar
Abstract:
A Bayesian feature allocation model (FAM) is presented for identifying cell subpopulations based on multiple samples of cell surface or intracellular marker expression level data obtained by cytometry by time of flight (CyTOF). Cell subpopulations are characterized by differences in expression patterns of makers, and individual cells are clustered into the subpopulations based on the patterns of t…
▽ More
A Bayesian feature allocation model (FAM) is presented for identifying cell subpopulations based on multiple samples of cell surface or intracellular marker expression level data obtained by cytometry by time of flight (CyTOF). Cell subpopulations are characterized by differences in expression patterns of makers, and individual cells are clustered into the subpopulations based on the patterns of their observed expression levels. A finite Indian buffet process is used to model subpopulations as latent features, and a model-based method based on these latent feature subpopulations is used to construct cell clusters within each sample. Non-ignorable missing data due to technical artifacts in mass cytometry instruments are accounted for by defining a static missing data mechanism. In contrast to conventional cell clustering methods based on observed marker expression levels that are applied separately to different samples, the FAM based method can be applied simultaneously to multiple samples, and can identify important cell subpopulations likely to be missed by conventional clustering. The proposed FAM based method is applied to jointly analyze three datasets, generated by CyTOF, to study natural killer (NK) cells. Because the subpopulations identified by the FAM may define novel NK cell subsets, this statistical analysis may provide useful information about the biology of NK cells and their potential role in cancer immunotherapy which may lead, in turn, to development of improved cellular therapies. Simulation studies of the proposed method's behavior under two cases of known subpopulations also are presented, followed by analysis of the CyTOF NK cell surface marker data.
△ Less
Submitted 20 February, 2020;
originally announced February 2020.
-
A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling
Authors:
Yanxun Xu,
Peter F. Thall,
Peter Mueller,
Mehran J. Reza
Abstract:
We propose a Bayesian nonparametric utility-based group sequential design for a randomized clinical trial to compare a gel sealant to standard care for resolving air leaks after pulmonary resection. Clinically, resolving air leaks in the days soon after surgery is highly important, since longer resolution time produces undesirable complications that require extended hospitalization. The problem of…
▽ More
We propose a Bayesian nonparametric utility-based group sequential design for a randomized clinical trial to compare a gel sealant to standard care for resolving air leaks after pulmonary resection. Clinically, resolving air leaks in the days soon after surgery is highly important, since longer resolution time produces undesirable complications that require extended hospitalization. The problem of comparing treatments is complicated by the fact that the resolution time distributions are skewed and multi-modal, so using means is misleading. We address these challenges by assuming Bayesian nonparametric probability models for the resolution time distributions and basing the comparative test on weighted means. The weights are elicited as clinical utilities of the resolution times. The proposed design uses posterior expected utilities as group sequential test criteria. The procedure's frequentist properties are studied by extensive simulations.
△ Less
Submitted 18 July, 2016; v1 submitted 25 June, 2015;
originally announced June 2015.
-
Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times
Authors:
Yanxun Xu,
Peter Mueller,
Abdus S. Wahed,
Peter F. Thall
Abstract:
Dynamic treatment regimes in oncology and other disease areas often can be characterized by an alternating sequence of treatments or other actions and transition times between disease states. The sequence of transition states may vary substantially from patient to patient, depending on how the regime plays out, and in practice there often are many possible counterfactual outcome sequences. For eva…
▽ More
Dynamic treatment regimes in oncology and other disease areas often can be characterized by an alternating sequence of treatments or other actions and transition times between disease states. The sequence of transition states may vary substantially from patient to patient, depending on how the regime plays out, and in practice there often are many possible counterfactual outcome sequences. For evaluating the regimes, the mean final overall time may be expressed as a weighted average of the means of all possible sums of successive transitions times. A common example arises in cancer therapies where the transition times between various sequences of treatments, disease remission, disease progression, and death characterize overall survival time. For the general setting, we propose estimating mean overall outcome time by assuming a Bayesian nonparametric regression model for the logarithm of each transition time. A dependent Dirichlet process prior with Gaussian process base measure (DDP-GP) is assumed, and a joint posterior is obtained by Markov chain Monte Carlo (MCMC) sampling. We provide general guidelines for constructing a prior using empirical Bayes methods. We compare the proposed approach with inverse probability of treatment weighting. These comparisons are done by simulation studies of both single-stage and multi-stage regimes, with treatment assignment depending on baseline covariates. The method is applied to analyze a dataset arising from a clinical trial involving multi-stage chemotherapy regimes for acute leukemia. An R program for implementing the DDP-GP-based Bayesian nonparametric analysis is freely available at https://www.ma.utexas.edu/users/yxu/.
△ Less
Submitted 12 May, 2014;
originally announced May 2014.
-
Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials
Authors:
Peter F. Thall
Abstract:
An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "phase I/II" trials, these experiments typically have the nominal scientific goal of determining an acceptable dose, most often based on adverse event probabilities. This arose from a tradition of phase I trials to evaluate…
▽ More
An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "phase I/II" trials, these experiments typically have the nominal scientific goal of determining an acceptable dose, most often based on adverse event probabilities. This arose from a tradition of phase I trials to evaluate cytotoxic agents for treating cancer, although some methods may be applied in other medical settings, such as treatment of stroke or immunological diseases. Most modern statistical designs for early phase trials include model-based, outcome-adaptive decision rules that choose doses for successive patient cohorts based on data from previous patients in the trial. Such designs have seen limited use in clinical practice, however, due to their complexity, the requirement of intensive, computer-based data monitoring, and the medical community's resistance to change. Still, many actual applications of model-based outcome-adaptive designs have been remarkably successful in terms of both patient benefit and scientific outcome. In this paper I will review several Bayesian early phase trial designs that were tailored to accommodate specific complexities of the treatment regime and patient outcomes in particular clinical settings.
△ Less
Submitted 30 November, 2010;
originally announced November 2010.
